 The development of vaccines for autoimmune diseases involves two main types, tollerogenic and immunogenic vaccines. Tollerogenic vaccines eliminate T cells reactive to self antigens, while immunogenic vaccines switch the immune response from TH1, TH17 to TH2 immunity by inducing an anti-inflammatory response. DNA vaccines also induce a TH2 immunity and can benefit from the presence of adjuvants that enhance the immune response. Glaterama, few-cosylated glycans, and plant-arrived few-cosylated tritapine glycosides are promising sole TH2 adjuvants that induce an anti-inflammatory immunity without abrogating pro-inflammatory TH1, TH17 immunities. This article was authored by Dante J. Marciani.